Table 2. 1-, 3-, 5-, and 10-year relative survival of patients with SCLC stratified by disease stage.
Relative survival (%) | Years since diagnosis | |||||||
1 | 3 | 5 | 10 | |||||
Survival | (95% CI) | Survival | (95% CI) | Survival | (95% CI) | Survival | (95% CI) | |
Limited Disease (LD) | ||||||||
Period 1 (1993–1998) | 56.8 | (54.3–59.1) | 20.3 | (18.3–22.3) | 16.8 | (14.9–18.7) | 12.4 | (10.6–14.4) |
Period 2 (1999–2001) | 63.6 | (60.5–66.6) | 26.2 | (23.4–29.1) | 21.1 | (18.4–23.8) | 16.1 | (13.5–18.8) |
Period 3 (2002–2006) | 66.9 | (64.5–69.2) | 27.0 | (24.8–29.3) | 19.9 | (17.8–22.0) | ||
Period 3 (perioda) | 66.2 | (63.8–68.5) | 27.2 | (25.0–29.5) | 21.4 | (19.3–23.6) | 15.6 | (13.4–18.0) |
Extensive Disease (ED) | ||||||||
Period 1 (1993–1998) | 27.7 | (25.6–29.8) | 3.4 | (2.6–4.4) | 2.3 | (1.6–3.1) | 1.2 | (0.7–1.8) |
Period 2 (1999–2001) | 33.0 | (30.1–35.9) | 5.2 | (3.9–6.7) | 2.8 | (1.9–4.0) | 1.7 | (1.0–2.9) |
Period 3 (2002–2006) | 34.3 | (32.3–36.4) | 4.3 | (3.5–5.3) | 2.0 | (1.4–2.7) | ||
Period 3 (perioda) | 34.8 | (32.8–36.9) | 5.0 | (4.0–6.0) | 2.7 | (2.0–3.6) | 1.4 | (0.8–2.3) |
CI, confidence interval; ED, extensive disease; LD, limited disease; SCLC, small-cell lung cancer.
aRelative survival and CIs were estimated using the period method. Survival data of patients followed between 2002 and 2006 were used.